View in EDS

Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical Trial.

Saved in:
Bibliographic Details
Title: Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical Trial.
Authors: Willis BA; Work Completed While an Employee of Eli Lilly and Company. Current Affiliation: Eisai Inc., Nutley, NJ, USA., Lo AC; Work Completed While an Employee of Eli Lilly and Company., Dage JL; Work Completed While an Employee of Eli Lilly and Company. Current Affiliation: Indiana University School of Medicine, Indianapolis, IN, USA., Shcherbinin S; Eli Lilly and Company, Indianapolis, IN, USA., Chinchen L; Eli Lilly and Company, Bracknell, UK., Andersen SW; Eli Lilly and Company, Indianapolis, IN, USA., LaBell ES; Eli Lilly and Company, Indianapolis, IN, USA., Perahia DGS; Eli Lilly and Company, Bracknell, UK., Hauck PM; Eli Lilly and Company, Indianapolis, IN, USA., Lowe SL; Lilly Centre for Clinical Pharmacology, Singapore.
Source: Journal of Alzheimer's disease reports [J Alzheimers Dis Rep] 2023 Sep 15; Vol. 7 (1), pp. 1015-1024. Date of Electronic Publication: 2023 Sep 15 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Sage Publications Country of Publication: United States NLM ID: 101705500 Publication Model: eCollection Cited Medium: Internet ISSN: 2542-4823 (Electronic) Linking ISSN: 25424823 NLM ISO Abbreviation: J Alzheimers Dis Rep Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37849628
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Willis+BA%22">Willis BA</searchLink>; Work Completed While an Employee of Eli Lilly and Company. Current Affiliation: Eisai Inc., Nutley, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Lo+AC%22">Lo AC</searchLink>; Work Completed While an Employee of Eli Lilly and Company.<br /><searchLink fieldCode="AU" term="%22Dage+JL%22">Dage JL</searchLink>; Work Completed While an Employee of Eli Lilly and Company. Current Affiliation: Indiana University School of Medicine, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Shcherbinin+S%22">Shcherbinin S</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Chinchen+L%22">Chinchen L</searchLink>; Eli Lilly and Company, Bracknell, UK.<br /><searchLink fieldCode="AU" term="%22Andersen+SW%22">Andersen SW</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22LaBell+ES%22">LaBell ES</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Perahia+DGS%22">Perahia DGS</searchLink>; Eli Lilly and Company, Bracknell, UK.<br /><searchLink fieldCode="AU" term="%22Hauck+PM%22">Hauck PM</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Lowe+SL%22">Lowe SL</searchLink>; Lilly Centre for Clinical Pharmacology, Singapore.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101705500%22">Journal of Alzheimer's disease reports</searchLink> [J Alzheimers Dis Rep] 2023 Sep 15; Vol. 7 (1), pp. 1015-1024. <i>Date of Electronic Publication: </i>2023 Sep 15 (<i>Print Publication: </i>2023).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Sage+Publications%22">Sage Publications </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101705500 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2542-4823 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225424823%22">25424823 </searchLink><i>NLM ISO Abbreviation: </i>J Alzheimers Dis Rep <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37849628
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3233/ADR-230012
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1015
    Titles:
      – TitleFull: Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Willis BA
      – PersonEntity:
          Name:
            NameFull: Lo AC
      – PersonEntity:
          Name:
            NameFull: Dage JL
      – PersonEntity:
          Name:
            NameFull: Shcherbinin S
      – PersonEntity:
          Name:
            NameFull: Chinchen L
      – PersonEntity:
          Name:
            NameFull: Andersen SW
      – PersonEntity:
          Name:
            NameFull: LaBell ES
      – PersonEntity:
          Name:
            NameFull: Perahia DGS
      – PersonEntity:
          Name:
            NameFull: Hauck PM
      – PersonEntity:
          Name:
            NameFull: Lowe SL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 09
              Text: 2023 Sep 15
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2542-4823
          Numbering:
            – Type: volume
              Value: 7
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal of Alzheimer's disease reports
              Type: main
ResultId 1